SAN DIEGO, March 13 /PRNewswire-FirstCall/ -- Nanogen, Inc. , developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,989,086, "Channel-less Separation of Bioparticles on a Bioelectronic Chip by Dielectrophoresis" by the U.S. Patent and Trademark Office. The '086 patent relates to a method of separating biomolecules or cell particles on a chip using electronic current to preferentially attract specific molecules or cellular components.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGO )
The patent describes the configuration of a device that can integrate sample preparation and nucleic acid amplification and detection on an electronic chip. The chip can be used to separate, lyse and enzymatically treat a biological sample in order to expose nucleic acids. Those nucleic acids can then be amplified, if necessary, and detected on the same chip. The work to develop this technology was supported by the U.S. Department of Commerce under the Advanced Technology Program.
Nanogen was also issued U.S. Patent No. 6,998,243, entitled "Biopolymer Marker Indicative of Disease State Having a Molecular Weight of 1793 Daltons."
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip(R) electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biowarfare applications. For additional information please visit Nanogen's website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Photo: http://www.newscom.com/cgi-bin/prnh/20050803/LAW135LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comNanogen, Inc.CONTACT: Robert Saltmarsh, Chief Financial Officer of Nanogen, Inc.,+1-858-410-4600; or Media & Investor Relations, Pam Lord of Porter NovelliLife Sciences, +1-858-527-3494, plord@pnlifesciences.com, for Nanogen, Inc.
Web site: http://www.nanogen.com//
